Exelixis (EXEL) Competitors

Biogen (NASDAQ:BIIB) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Do analysts rate BIIB or EXEL?

Biogen presently has a consensus target price of $185.74, suggesting a potential upside of 34.01%. Exelixis has a consensus target price of $44.06, suggesting a potential upside of 15.00%. Given Biogen's higher possible upside, equities analysts clearly believe Biogen is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	21 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.34
Exelixis	1 Sell rating(s)	8 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.55

Which has more risk and volatility, BIIB or EXEL?

Biogen has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.

Is BIIB or EXEL more profitable?

Exelixis has a net margin of 27.01% compared to Biogen's net margin of 15.31%. Exelixis' return on equity of 27.47% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	15.31%	13.85%	8.32%
Exelixis	27.01%	27.47%	20.88%

Which has better earnings and valuation, BIIB or EXEL?

Biogen has higher revenue and earnings than Exelixis. Biogen is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.68B	2.10	$1.63B	$10.46	13.25
Exelixis	$2.23B	4.62	$521.27M	$2.08	18.42

Do insiders and institutionals hold more shares of BIIB or EXEL?

87.9% of Biogen shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 2.8% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Does the media refer more to BIIB or EXEL?

In the previous week, Biogen had 20 more articles in the media than Exelixis. MarketBeat recorded 38 mentions for Biogen and 18 mentions for Exelixis. Exelixis' average media sentiment score of 1.16 beat Biogen's score of 1.06 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	22 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	11 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Exelixis beats Biogen on 10 of the 16 factors compared between the two stocks.